CD8A and neoplasm: A recent study demonstrated that VEGF-A produced in the tumor microenvironment increased the expression of PD-1 and other inhibitory checkpoints involved in CD8+ T-cell exhaustion, which could be counteracted by antiangiogenic agents targeting VEGF-A-VEGFR [27].